ExpertiseUpdated on 13 November 2025
New Approach Methodologies (NAM) Training Program
Application Scientist at Dynamic42 GmbH
Germany
About
This training provides an overview of New Approach Methodologies (NAMs) and their relevance in contemporary in vitro research. Participants will learn the scientific principles behind NAMs, how these methods complement or replace traditional animal-based testing, and the contexts in which they can be applied. The session introduces key concepts such as human-relevant model systems, study design considerations, and data interpretation. Designed for researchers, students, and professionals seeking a foundational understanding of NAMs, this training focuses on education, awareness, and responsible scientific practice without promoting any specific products or services.
Field
- DISEASE AREA | Cancer
- DISEASE AREA | Inflammation / Autoimmune Diseases
- DISEASE AREA | Infectious Diseases
- DISEASE AREA | Metabolic Diseases
- DISEASE AREA | Other
- MEDICINE | Drug Target Discovery
- MEDICINE | Drug Screening
- MEDICINE | Gene Therapy
- MEDICINE | Cell Therapy
- MEDICINE | RNA-based Therapy
- TECHNOLOGY | Bioengineering
- TECHNOLOGY | Personalized disease models
- TECHNOLOGY | Other
Attached files
Organisation
Similar opportunities
Expertise
Tailored Biomarker Solutions for your Clinical Programs
- DISEASE AREA | Cancer
- MEDICINE | Diagnostics
- MEDICINE | Cell Therapy
- MEDICINE | Early Detection
- MEDICINE | RNA-based Therapy
- MEDICINE | Therapy Monitoring
- MEDICINE | Biomarker Discovery
- DISEASE AREA | Metabolic Diseases
- DISEASE AREA | Infectious Diseases
- TECHNOLOGY | (Single-cell) multi-omics
- DISEASE AREA | Inflammation / Autoimmune Diseases
Andreas Hüser
CEO at CheckImmune GmbH
Berlin, Germany
Expertise
- MEDICINE | Other
- TECHNOLOGY | Other
- DISEASE AREA | Cancer
- DISEASE AREA | Other
- MEDICINE | Diagnostics
- MEDICINE | Gene Therapy
- MEDICINE | Liquid Biopsy
- MEDICINE | Drug Screening
- MEDICINE | Early Detection
- MEDICINE | RNA-based Therapy
- MEDICINE | Biomarker Discovery
- MEDICINE | Drug Target Discovery
- DISEASE AREA | Infectious Diseases
- DISEASE AREA | Cardiovascular Diseases
Ismahen Ammar
Technical Sales Specialist at Illumina GmbH
Berlin, Germany
Investment
Selective Inhibitors of Genotoxic Stress Induced NFκB Pathway for Cancer Therapy
- Disease Area
- Seed & Development
- Biomedical Research, Medicine, Human Health
Beatrice Pöschel
Technologie-Managerin at Max Delbrück Center for Molecular Medicine
Berlin, Germany